Co-Diagnostics shares are trading higher after the company announced it has completed the assay development strategy for the Bundibugyo virus. On May 17, the World Health Organization declared that the Ebola outbreak caused by the Bundibugyo virus strain in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern.